214 related articles for article (PubMed ID: 29775688)
1. Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors.
Curigliano G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):253-258. PubMed ID: 29775688
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer genomics and immuno-oncological markers to guide immune therapies.
Hammerl D; Smid M; Timmermans AM; Sleijfer S; Martens JWM; Debets R
Semin Cancer Biol; 2018 Oct; 52(Pt 2):178-188. PubMed ID: 29104025
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
Luen SJ; Savas P; Fox SB; Salgado R; Loi S
Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
[TBL] [Abstract][Full Text] [Related]
4. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R
Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336
[TBL] [Abstract][Full Text] [Related]
5. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB; Jazaeri AA
Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers.
Di Tucci C; Schiavi MC; Faiano P; D'Oria O; Prata G; Sciuga V; Giannini A; Palaia I; Muzii L; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Aug; 128():30-42. PubMed ID: 29958629
[TBL] [Abstract][Full Text] [Related]
8. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
Varn FS; Schaafsma E; Wang Y; Cheng C
Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
[TBL] [Abstract][Full Text] [Related]
9. Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
Passiglia F; Caglevic C; Giovannetti E; Pinto JA; Manca P; Taverna S; Listì A; Gil-Bazo I; Raez LE; Russo A; Rolfo C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):259-268. PubMed ID: 29391205
[TBL] [Abstract][Full Text] [Related]
10. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
12. Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities.
Azarianpour S; Corredor G; Bera K; Leo P; Fu P; Toro P; Joehlin-Price A; Mokhtari M; Mahdi H; Madabhushi A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115363
[TBL] [Abstract][Full Text] [Related]
13. Genomic insights in gynecologic cancer.
Roddy E; Chapman J
Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
[TBL] [Abstract][Full Text] [Related]
14. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
Davoli T; Uno H; Wooten EC; Elledge SJ
Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
[TBL] [Abstract][Full Text] [Related]
15. The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
Xu Y; Zuo F; Wang H; Jing J; He X
Front Immunol; 2022; 13():1045957. PubMed ID: 36389711
[TBL] [Abstract][Full Text] [Related]
16. An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.
Castellano T; Moore KN; Holman LL
Clin Ther; 2018 Mar; 40(3):372-388. PubMed ID: 29530456
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.
Lee B; Hutchinson R; Wong HL; Tie J; Putoczki T; Tran B; Gibbs P; Christie M
Semin Cancer Biol; 2018 Oct; 52(Pt 2):241-252. PubMed ID: 29258858
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
[TBL] [Abstract][Full Text] [Related]
20. Editorial: Novel immune markers and predictive models for immunotherapy and prognosis in breast and gynecological cancers.
Wang F; Huang Q; Guo S; Traverso A; Teng F; Liu C
Front Immunol; 2024; 15():1431245. PubMed ID: 38868773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
